Elanco Animal Health
Elanco Animal Health Incorporated
Key figures
Period Jan 2025 to Dec 2025ConsolidatedU.S. GAAP
RevenueDisclosed
US$4.7B
Operating marginCalculated
Could not be retrieved
Net assets to total assetsCalculated
49.0%
Company profile
Tables scroll sideways
Disclosed data
Profitability
Could not be retrieved
Growth (revenue, 4-year average)
★☆☆☆☆position among all companies
-0.3%
Capital efficiency
★☆☆☆☆position among all companies
-3.5%
Revenue and profit
Performance, financial position and capital allocation
Elanco Animal Health
Recent performance trends
Elanco Animal Health
Cash flow trends
Consolidated indicators (8 items)
| Item | 4 years ago | 3 years ago | 2 years ago | Last year | This year |
|---|---|---|---|---|---|
| Net sales | US$4.8 billion | US$4.4 billion | US$4.4 billion | US$4.4 billion | US$4.7 billion |
| Net income | US$-0.5 billion | US$-78.00 million | US$-1.2 billion | US$0.3 billion | US$-0.2 billion |
| Total assets | US$16.5 billion | US$15.5 billion | US$14.4 billion | US$12.6 billion | US$13.4 billion |
| Shareholders' equity | US$7.5 billion | US$7.3 billion | US$6.2 billion | US$6.1 billion | US$6.5 billion |
| Net cash provided by (used in) operating activities | US$0.5 billion | US$0.5 billion | US$0.3 billion | US$0.5 billion | US$0.6 billion |
| Net cash provided by (used in) investing activities | US$-0.5 billion | US$-0.2 billion | US$-0.2 billion | US$1.2 billion | US$-0.3 billion |
| Net cash provided by (used in) financing activities | US$0.2 billion | US$-0.5 billion | US$-83.00 million | US$-1.5 billion | US$-0.3 billion |
| Cash and cash equivalents | US$0.6 billion | US$0.3 billion | US$0.4 billion | US$0.5 billion | US$0.5 billion |
Revenue scale in the same industry
Elanco Animal Health
Chemicals and pharmaceuticals: 56 companies · revenue · largest first・each company’s latest fiscal year・Consolidated・Disclosed
- 1 Johnson & JohnsonFY Dec 2025 US$94.2B
- 2 Procter & GambleFY Jun 2026 US$87.0B
- 3 ELI Lilly ANDFY Dec 2025 US$65.2B
- … 38 companies
- 42 AlbemarleFY Dec 2025 US$5.1B
- 43 Axalta Coating SystemsFY Dec 2025 US$5.1B
- 44 Elanco Animal HealthThis companyFY Dec 2025 US$4.7B
- 45 Idexx LaboratoriesFY Dec 2025 US$4.3B
- 46 Jazz PharmaceuticalsFY Dec 2025 US$4.3B
- … 10 companies
Sources and methodology
Basic indicators
| Item | Value | Consolidated / Non-consolidated | Source |
|---|---|---|---|
| Purchase of property, plant and equipment | US$0.3 billion | Consolidated | Disclosed |
| Cash and cash equivalents | US$0.5 billion | Consolidated | Disclosed |
| Net cash provided by (used in) financing activities | US$-0.3 billion | Consolidated | Disclosed |
| Net cash provided by (used in) investing activities | US$-0.3 billion | Consolidated | Disclosed |
| Net cash provided by (used in) operating activities | US$0.6 billion | Consolidated | Disclosed |
| Depreciation and amortization | US$0.7 billion | Consolidated | Disclosed |
| Net assets | US$6.5 billion | Consolidated | Disclosed |
| Net sales | US$4.7 billion | Consolidated | Disclosed |
| Net income | US$-0.2 billion | Consolidated | Disclosed |
| Total assets | US$13.4 billion | Consolidated | Disclosed |
| Operating margin | Cannot be calculated | Not applicable | Not calculated (no operating income in this year's 10-K) |
| Net assets to total assets | 49.0% | Consolidated | Calculated |
| Net margin | -4.9% | Consolidated | Calculated |
| Return on equity | -3.5% | Consolidated | Calculated |